Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase inhibitors. However, for the rare EGFR deletion-insertion mutation of exon 18, there is very little evidence regarding the effectiveness of tyrosine kinase in...

Full description

Bibliographic Details
Main Authors: Michael Cekay, Philipp F. Arndt, Rio Dumitrascu, Rajkumar Savai, Andreas Braeuninger, Stefan Gattenloehner, Dagmar Steiner, Fritz Roller, Khodr Tello, Katja Hattar, Werner Seeger, Ulf Sibelius, Friedrich Grimminger, Bastian Eul
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
EGFR mutation
tyrosine kinase inhibitors (TKIs)
Osimertinib
EGFR Exon 18 insertion
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1182391/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1182391/full

Similar Items